Alimemazine [1], hypnotics ---> SmPC of [1] of eMC
The sedative effects of phenothiazines may be intensified (additively) by hypnotics
Alizapride, hypnotics
Increased CNS depressant effect
Alprazolam [1], hypnotics ---> SmPC of [1] of eMC
Enhancement of the central depressive effect may occur in case of concomitant use of alprazolam with other CNS depressants
Amitriptyline, hypnotics
Concomitant use enhances the sedative effect.
Antihistamines, hypnotics
Antihistamines potentiate the sedative effects of hypnotics
Azelastine, hypnotics
Azelastine may enhance sedation effects of other medicinal products as tranquilizers, hypnotics and alcohol
Benperidol [1], hypnotics ---> SmPC of [1] of eMC
Benperidol can increase the CNS depression produced by other CNS-depressant drugs
Benzodiazepines, hypnotics
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Bromazepam, hypnotics
Enhancement of the depressor effect on the central nervous system
Bromperidol, hypnotics
The co-administration may cause increased tiredness, drowsiness and respiratory disorders
Brotizolam, hypnotics
The co-administration of brotizolam with other central nervous system depressants may enhance the central nervous depressant effect
Carbamazepine, hypnotics
The co-administration may promote the neurological adverse effects.
Carisoprodol, hypnotics
The co-administration may enhance the depressive effect on the central nervous system.
Celiprolol, hypnotics
Additive effect
Chloral hydrate, hypnotics
Increased hypnotic effect
Chlordiazepoxide [1], hypnotics ---> SmPC of [1] of eMC
Enhancement of the central depressive effect may occur if chlordiazepoxide is combined with other CNS-depressant drugs.
Chlorphenamine, hypnotics
Chlorphenamine may have an additive effect when used concurrently with hypnotics causing potentiation of drowsiness.
Chlorpromazine [1], hypnotics ---> SmPC of [1] of eMC
The co-administration may increase the CNS depressant effect
Chlorprothixene, hypnotics
The co-administration of chlorprothixene with CNS depressants may cause strong sedation or respiratory depression
Cilazapril, hypnotics
Increased hypotensive effect.
Cinitapride, hypnotics
The co-administration enhances the sedative effects
Cinnarizine, hypnotics
Concurrent use of cinnarizine and CNS depressants may potentiate the sedative effects
Clebopride, hypnotics
Clebopride may enhance the sedative effects
Clemastine, hypnotics
Antihistamines potentiate the sedative effects of hypnotics
Clobazam [1], hypnotics ---> SmPC of [1] of eMC
Especially when clobazam is administered at higher doses, an enhancement of the central depressive effect may occur in cases of combination with other central depressive drugs
Clonidine [1], hypnotics ---> SmPC of [1] of eMC
The effect of hypnotics could theoretically be potentiated by clonidine.
Cloperastine, hypnotics
Increased CNS depressant effect
Codeine [1], hypnotics ---> SmPC of [1] of eMC
Enhanced sedative and hypotensive effect, increased risk of respiratory depression
Cyclizine [1], hypnotics ---> SmPC of [1] of eMC
Cyclizine may have additive effects with other central nervous system depressants
Cyproheptadine [1], hypnotics ---> SmPC of [1] of eMC
Antihistamines may have additive effects with other CNS depressants
Dantrolene, hypnotics
The co-administration of dantrolene and CNS depressants should be avoided due to the adverse reactions of dantrolene may be enhanced (specially the CNS depressant effect and muscle weakness)
Dapoxetine [1], hypnotics ---> SmPC of [1] of eMC
Caution is advised if the concomitant administration of dapoxetine and CNS active medicinal products is required
Dexchlorpheniramine, hypnotics
The combination of dexchlorpheniramine with other CNS depressants may enhance the CNS depressant effect
Dexmedetomidine [1], hypnotics ---> SmPC of [1] of EMA
Co-administration of dexmedetomidine with anaesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects, including sedative, anaesthetic and cardiorespiratory effects.
Diamorphine [1], hypnotics ---> SmPC of [1] of eMC
The depressant effects of diamorphine may be exaggerated and prolonged by hypnotics
Diazepam [1], hypnotics ---> SmPC of [1] of eMC
Enhancement of the central depressive effect may occur
Dihydralazine, hypnotics
The co-administration may enhance the hypotensive and hypnotic effect
Dimenhydrinate, hypnotics
Dimenhydrinate may increase the effects of other CNS depressors and enhance the sedative effects
Dipotassium clorazepate, hypnotics
The combination of CNS depressors may mutually potentiate the depressor effect on the CNS
Dixyrazine, hypnotics
Dixyrazine enhances the effect of hypnotic
Doxepin, hypnotics
The co-administration may enhance the central sedative effect
Doxylamine, hypnotics
Antihistaminic agents have additive effects with other CNS depressants
Enalapril/hydrochlorothiazide, hypnotics
Increased hypotensive effect.
Esketamine, hypnotics
The co-administration may prolong the esketamine duration of effect and weaken the adverse effects
Felodipine/ramipril [1], hypnotics ---> SmPC of [1] of eMC
Potentiation of the antihypertensive effect is to be anticipated.
Fentanyl [1], hypnotics ---> SmPC of [1] of EMA
The concomitant use of fentanyl with other central nervous system depressants may produce additive depressant effects.
Flunarizine, hypnotics
Concomitant use of flunarizine with alcohol, hypnotics or other tranquilizers may enhance the sedative effect of flunarizine
Flunitrazepam, hypnotics
The co-administration may cause a mutual potentiation of effects.
Flupentixol [1], hypnotics ---> SmPC of [1] of eMC
In common with other antipsychotics, flupentixol enhances the response to other CNS depressants.
Fluphenazine [1], hypnotics ---> SmPC of [1] of eMC
Phenothiazines may increase the central nervous system depression produced by other CNS depressants
Flurazepam [1], hypnotics ---> SmPC of [1] of eMC
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Guanfacin [1], hypnotics ---> SmPC of [1] of EMA
Caution should be used when Intuniv is administered concomitantly with CNS depressant medicinal products due to the potential for additive pharmacodynamic effects such as sedation and somnolence.
Haloperidol [1], hypnotics ---> SmPC of [1] of eMC
In common with all neuroleptics, haloperidol can increase the central nervous system depression produced by other CNS-depressant drugs.
Hemp extract, hypnotics
Care should be taken as there may be an additive effect on sedation and muscle relaxing effects.
Hydrochlorothiazide, hypnotics
Increased hypotensive effect.
Hydrocodone, hypnotics
The co-administration of hydrocodone and other CNS depressants may enhance the sedative and respiratory depressor effects
Hydromorphone [1], hypnotics ---> SmPC of [1] of eMC
Centrally acting drugs may interact with hydromorphone and potentiate the effects of either drug, e.g. sedation, respiratory depression
Hypnotics, interferon alfa-2b [2] ---> SmPC of [2] of EMA
The concomitant use should be done with caution
Hypnotics, ketamine [2] ---> SmPC of [2] of eMC
Reduced doses of ketamine may be required with concurrent administration of other anxiolytics, sedatives and hypnotics.
Hypnotics, labetalol
Possible enhancement of hypotensive effect of labetalol
Hypnotics, levomepromazine
The co-administration of levomepromazine with other central nervous depressants will cause a greater depressant effect on central nervous system
Hypnotics, levomethadone
Enhancement of effects and adverse effects, particularly respiratory depression
Hypnotics, lofepramine
An enhanced sedative effect has been reported when taken hypnotics with lofepramine.
Hypnotics, loprazolam [2] ---> SmPC of [2] of eMC
The risk of a withdrawal syndrome occurring is increased when loprazolam is combined with other benzodiazepines prescribed as anxiolytics or hypnotics.
Hypnotics, lorazepam [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur if lorazepam is combined with other CNS depressants
Hypnotics, lormetazepam
The benzodiazepines, including lormetazepam produce additive CNS depressant effects when co-administered with other medications which themselves produce CNS depression
Hypnotics, loxapine [2] ---> SmPC of [2] of EMA
The co-administration may be associated with excessive sedation and respiratory depression or respiratory failure.
Hypnotics, medazepam
The co-administration of medazepam with other central nervous system depressants may enhance the central nervous depressant effect.
Hypnotics, melperone
An enhancement of the central depressive effect may occur in cases of combination of melperone with other central depressive drugs
Hypnotics, meprobamate
Meprobamate may increase the effects of concurrently administered central nervous system depressants.
Hypnotics, meptazinol
Enhanced sedative effect.
Hypnotics, mesuximide
Contraindicated
Hypnotics, methadone [2] ---> SmPC of [2] of eMC
The depressant effects of methadone are likely to be enhanced by depressants of the CNS. As well as CNS depression, there may be respiratory depression and/or hypotension.
Hypnotics, methyldopa
Concomitant use of methyldopa and hypnotics may enhance the hypotensive effect.
Hypnotics, metoclopramide
The co-administration may mutually enhance the sedative effects of the CNS. The combination requires caution
Hypnotics, metoprolol [2] ---> SmPC of [2] of eMC
Concomitant use of metoprolol with hypnotics may result in an enhanced hypotensive effect.
Hypnotics, mianserin
Mianserin may enhance the central depressive effect of hypnotic agent
Hypnotics, midazolam [2] ---> SmPC of [2] of EMA
The co-administration of midazolam with other sedative/hypnotic agents and CNS depressants, including alcohol, is likely to result in enhanced sedation and respiratory depression.
Hypnotics, morphine [2] ---> SmPC of [2] of eMC
Morphine sulphate potentiates the effects of other central nervous depressants
Hypnotics, moxonidine [2] ---> SmPC of [2] of eMC
Moxonidine can potentiate the sedative effect of hypnotics
Hypnotics, naphazoline
Possible potentiation of the central depression
Hypnotics, narcotine
Noscapine with other CNS depressant drugs may increase the sedation and somnolence of the CNS depressants
Hypnotics, neuroleptics
Potentiation may occur if antipsychotic drugs are combined with CNS depressants
Hypnotics, nitrazepam
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Hypnotics, oxatomide
The co-administration may increase the CNS depressant effect
Hypnotics, oxazepam
Enhancement of other CNS depressant drugs
Hypnotics, oxomemazine
Enhancement of CNS depressant effect
Hypnotics, oxycodone [2] ---> SmPC of [2] of eMC
Central nervous system depressants can enhance the adverse reactions of oxycodone, in particular respiratory depression.
Hypnotics, paliperidone [2] ---> SmPC of [2] of EMA
Given the primary CNS effects of paliperidone, it should be used with caution in combination with other centrally acting medicines.
Hypnotics, pentoxyverine
The use of CNS-depressors may enhance the sedative and respiratory depressive effects
Hypnotics, perphenazine
Risk of sedation and/or toxicity when perphenazine is administered with CNS depressants
Hypnotics, pethidine [2] ---> SmPC of [2] of eMC
The central depressant effects of pethidine may be potentiated by the concurrent use of other CNS depressants; respiratory depression and profound sedation or coma may occur.
Hypnotics, phenobarbital [2] ---> SmPC of [2] of eMC
Concurrent administration of phenobarbital with other CNS depressants may lead to additive CNS depressant effects
Hypnotics, pholcodine
Pholcodine may enhance the sedative effect of central nervous system depressants
Hypnotics, pimozide [2] ---> SmPC of [2] of eMC
As with other neuroleptics, pimozide may increase the central nervous system depression produced by other CNS depressant drugs
Hypnotics, pipotiazine
The CNS depressant actions of neuroleptic agents may be intensified (additively) by other sedatives. Respiratory depression may occur.
Hypnotics, piritramide
The co-administration may enhance the adverse effects of piritramide, particularly respiratory depression
Hypnotics, pizotifen [2] ---> SmPC of [2] of eMC
The central effects of hypnotics may be enhanced by pizotifen.
Hypnotics, primidone
The central depressor effect of hypnotic may be enhanced by primidone
Hypnotics, promethazine
The co-administration of promethazine and other central nervous depressants can mutually enhance the effects and adverse reactions (particularly sedation and hypotension)
Hypnotics, propranolol
The co-administration may enhance the antihypertensive effect
Hypnotics, quazepam
The co-administration may cause a mutual potentiation of the depressor effect on the CNS
Hypnotics, risperidone [2] ---> SmPC of [2] of eMC
Risperidone should be used with caution in combination with other centrally-acting substances due to the increased risk of sedation.
Hypnotics, ropeginterferon alfa-2b [2] ---> SmPC of [2] of EMA
Narcotics, hypnotics or sedatives must be administered with caution when used concomitantly with ropeginterferon alfa-2b.
Hypnotics, selegiline [2] ---> SmPC of [2] of eMC
Concomitant use selegiline and central suppressant drugs and should be avoided.
Hypnotics, spirapril
Increased hypotensive effect.
Hypnotics, sufentanil
The co-administration may enhance the respiratory depressor effect of sufentanil
Hypnotics, sulpiride
Sulpiride enhances the sedative effect of hypnotic agent
Hypnotics, temazepam
Enhancement of the central depressive effect may occur if temazepam is combined with hypnotics
Hypnotics, tetrabenazine
The co-administration of tetrabenazine with CNS depressant drugs may have an additive sedative effect
Hypnotics, thalidomide [2] ---> SmPC of [2] of EMA
Thalidomide has sedative properties thus may enhance the sedative effects of other medicinal products
Hypnotics, tiapride
Enhancement of CNS depressant effect
Hypnotics, tramadol [2] ---> SmPC of [2] of eMC
Concomitant administration of tramadol with other centrally acting drugs may potentiate CNS depressant effects.
Hypnotics, tramazoline
Possible enhancement of the central depression
Hypnotics, trazodone [2] ---> SmPC of [2] of eMC
The sedative effects of hypnotic drugs may be intensified; dosage reduction is recommended in such instance.
Hypnotics, triamterene [2] ---> SmPC of [2] of eMC
The co-administration of triamterene and hypnotics may enhance the hypotensive effect
Hypnotics, triazolam
Increased CNS depressant effect with the co-administration of triazolam and hypnotic drugs may occur
Hypnotics, trifluoperazine [2] ---> SmPC of [2] of eMC
Potentiation may occur if antipsychotic drugs are combined with CNS depressants
Hypnotics, trimipramine [2] ---> SmPC of [2] of eMC
The co-administration of trimipramine with other CNS depressants may increase the CNS depressant effect.
Hypnotics, zaleplon [2] ---> SmPC of [2] of EMA
Combination of zaleplon with other CNS-acting compounds may enhance the central sedation
Hypnotics, zolpidem [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur in case of concomitant use of zolpidem with other central nervous system depressants
Hypnotics, zopiclone [2] ---> SmPC of [2] of eMC
The combination with CNS depressants an enhancement of the central depressive effect may occur.
Hypnotics, zotepine
The co-administration may cause a mutual potentiation of effects
Sedative hypnotics, sodium oxybate [2] ---> SmPC of [2] of EMA
When higher doses up to 9 g/d of sodium oxybate are combined with higher doses of hypnotics (within the recommended dose range) pharmacodynamic interactions associated with symptoms of CNS depression and/or respiratory depression cannot be excluded